Daily happenings?., page-247

I kinda agree, been sold down.

If an institute is eyeing off PTX-100 registrational trial they will want to keep this pegged and accumulate.

I think given that PTX-100 has orphan drug status, has an amazing safety profile and lastly shows promising efficacy...I think there's enough data already to warrant the registrational trial, regardless of what the latest data presents.

The most important consideration for the FDA granting a fast tracked registrational trial would be safety...PTX-100 is showing an amazing safety profile.

With PTX-100 targeting unmet needs, the FDA would have to be almost crazy not to fast track a limited registrational trial.

The share price is painful but this submarine will hit the surface again.

If PTX-100 moves to a registrational trial then the company will be primed for when the worm finally turns.

Going long on this baby.